Prior to the creation of Preora, Dr. Vadim Backman’s Northwestern University laboratory had received close to $20 million in NIH and NSF grants for the development of the core PWS NanocytologyTM platform, and an additional $7 million in fast-track SBIR/STTR grants to support the product and process development for commercialization.
The extraordinarily high level of grant funding serves as evidence of the clinical potential of our technology platform.
The company has completed a $3.65 million SAFE round, and is currently seeking financing through a Series A round. Preora is actively seeking commercial partnerships for the manufacture and distribution rights of its technologies.
Over the next three to five years, the company plans to license and/or sell its technologies to organizations that offer the best opportunity for adoption due to their regional or global commercialization capabilities and expertise.
Please contact John Hart, Preora Healthcare, president and CEO, at email@example.com, or Micah Litow, chief marketing and business development officer, firstname.lastname@example.org, to indicate interest or learn more about investment opportunities.